J.Safra Asset Management Corp Purchases New Shares in Quest Diagnostics Incorporated $DGX

J.Safra Asset Management Corp acquired a new stake in Quest Diagnostics Incorporated (NYSE:DGX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 4,621 shares of the medical research company’s stock, valued at approximately $979,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DGX. Key Financial Inc increased its position in Quest Diagnostics by 1,728.6% in the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 121 shares in the last quarter. Quattro Advisors LLC bought a new stake in shares of Quest Diagnostics during the fourth quarter valued at approximately $25,000. DV Equities LLC acquired a new stake in shares of Quest Diagnostics in the fourth quarter valued at approximately $27,000. Sittner & Nelson LLC bought a new position in Quest Diagnostics in the 4th quarter worth approximately $29,000. Finally, McIlrath & Eck LLC acquired a new position in Quest Diagnostics during the 4th quarter worth $32,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics Trading Up 0.0%

Shares of NYSE:DGX opened at $234.48 on Monday. The firm has a market cap of $25.88 billion, a price-to-earnings ratio of 24.89, a PEG ratio of 2.16 and a beta of 0.56. Quest Diagnostics Incorporated has a 12 month low of $171.18 and a 12 month high of $240.13. The company’s fifty day simple moving average is $215.60 and its 200 day simple moving average is $203.32. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.30. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The firm had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $2.97 billion. During the same quarter in the prior year, the company earned $2.62 EPS. The company’s revenue was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, research analysts forecast that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be given a dividend of $0.86 per share. The ex-dividend date of this dividend is Tuesday, October 6th. This represents a $3.44 annualized dividend and a yield of 1.5%. Quest Diagnostics’s dividend payout ratio is 36.52%.

More Quest Diagnostics News

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Broad-based earnings estimate increases: Zacks Research raised its FY2026 EPS forecast to $11.15 from $10.66, FY2027 to $11.71 from $11.50, and FY2028 to $12.90 from $12.50. The firm also increased estimates for Q3 and Q4 2026, Q1 through Q3 2027, and Q1 and Q2 2028. These revisions suggest improving expectations for Quest Diagnostics’ earnings growth. MarketBeat analyst estimate updates
• Positive Sentiment: Momentum remains favorable: A Zacks analysis highlighted DGX’s 2.29% weekly gain and evaluated whether the stock can continue to attract momentum investors. The coverage may reinforce positive sentiment following the recent advance. Quest Diagnostics Is Up 2.29% in One Week
• Positive Sentiment: Dividend support: Quest Diagnostics declared a quarterly dividend of $0.86 per share, payable October 21 to shareholders of record October 6. The annualized yield is approximately 1.5%, providing ongoing shareholder income. Quest Diagnostics dividend announcement
• Neutral Sentiment: One estimate was lowered: Zacks reduced its Q4 2027 EPS forecast to $2.90 from $3.05, partially offsetting the otherwise positive revisions. The firm’s full-year 2027 and 2028 forecasts nevertheless remain higher than its previous estimates.

Insider Buying and Selling at Quest Diagnostics

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 8,147 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the transaction, the senior vice president owned 13,510 shares of the company’s stock, valued at $2,702,000. The trade was a 37.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total value of $376,288.00. Following the transaction, the senior vice president directly owned 10,335 shares in the company, valued at $2,430,585.30. This trade represents a 13.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 19,747 shares of company stock worth $3,947,088 over the last ninety days. 0.88% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on DGX shares. UBS Group upped their price target on Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Weiss Ratings raised shares of Quest Diagnostics from a “buy (b+)” rating to a “buy (a-)” rating in a research note on Wednesday. Barclays increased their target price on Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Argus set a $260.00 price objective on shares of Quest Diagnostics in a research note on Wednesday, July 29th. Finally, Truist Financial upped their target price on shares of Quest Diagnostics from $225.00 to $250.00 and gave the company a “hold” rating in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $235.31.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.